Search Results
Your search for all items matches 34643 pages
Showing 1 - 50ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma
Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...
Pediatric ALL or Lymphoblastic Lymphoma: Reduced Induction Dexamethasone and High-Dose Methotrexate
In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients ...
Incidence Rates of Colorectal and Pancreatic Cancers Are Rising Most Among Young Adults
The incidence rates of colorectal and pancreatic adenocarcinomas have risen the most among young adults over the past 2 decades, suggesting the need for heightened awareness among clinicians for these diseases in this patient population, according to a report published by Bussetty et al in JAMA...
Link Between CT Scans and Future Cancer Incidence?
At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
Most Pediatric Cancer Deaths Occur in Regions of Conflict
Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology. Investigators from St. Jude Children’s Research Hospital, Duke University, and other institutions sought to reveal the relationship between...
FDA Approves Bevacizumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
Ideal Apixaban Dose for Cancer-Associated VTE
In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer. Study Details In the double-blind...
Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer. As stated by the investigators, “FOR46, a fully human antibody conjugated to monomethyl...
Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples
A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...
Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers
Neoantigen-specific tumor-infiltrating lymphocytes (TILs) in combination with the PD-1 inhibitor pembrolizumab led to responses among patients with metastatic gastrointestinal cancers, according to the results of a study from researchers at the National Institutes of Health published in Nature...
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
On April 11, 2025, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). Efficacy was evaluated in CheckMate-9DW (ClinicalTrials.gov identifier...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
Pausing vs Continuing BTK Inhibitors at Time of COVID-19 Vaccination in Patients With CLL
Researchers have found that patients with chronic lymphocytic leukemia (CLL) should continue to receive Bruton tyrosine kinase (BTK) inhibitors while being vaccinated against COVID-19 infections, according to a recent study published by Cook et al in The Lancet Haematology. Background CLL is the...
Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality. Study Details In the multicenter study, eligible...
Study Illuminates Disparities in Treatment, Survival in Metastatic Pancreatic Ductal Adenocarcinoma
Investigators may have uncovered factors that may impact the quality of cancer care and outcomes among patients with metastatic pancreatic ductal adenocarcinoma, according to a recent study published by Tsilimigras et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods...
American Cancer Society Launches CEO Search
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) announced the launch of a nationwide search to find the organizations’ next Chief Executive Officer (CEO). In November, the ACS Board of Directors appointed Wayne A.I. Frederick, MD, MBA, to serve as...
Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer
The results of a longitudinal cohort study published in JAMA suggest that frailty following adjuvant chemotherapy may be associated with long-term survival among older women with nonmetastatic breast cancer. Women who experienced rapid frailty progression, or nonresilience, following their...
Prostate Cancer: Biomarker Test May Predict GU Toxicity From SBRT
Researchers have developed, and now validated, a biomarker test to predict for genitourinary (GU) adverse events induced by stereotactic body radiotherapy (SBRT) in patients with prostate cancer, according to the results of a study published by Kishan et al in Clinical Cancer Research. The test,...
Crossing State Borders: Addressing Residential Barriers to Cancer Care
A high proportion of Medicare beneficiaries cross state borders to access cancer care, particularly patients residing in rural areas, according to a recent study published by Moen et al in JAMA Network Open. The findings have significant implications for telehealth policies and physician licensure, ...
FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer
On April 8, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) with the CTLA-4 inhibitor ipilimumab (Yervoy) for adult and pediatric patients aged 12 years and older with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch...
Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma
In a Japanese trial (JCOG0905) reported in the Journal of Clinical Oncology, Hiraga et al found no disease-free survival benefit with the addition of a higher dose of ifosfamide to methotrexate, doxorubicin, and cisplatin (MAP) in patients with newly diagnosed high-grade osteosarcoma with poor...
Talazoparib Plus Enzalutamide in Advanced Prostate Cancer: Patient-Reported Outcomes
In an analysis from the phase III TALAPRO-2 trial reported in The Lancet Oncology, Matsubara et al found that first-line talazoparib plus enzalutamide was associated with prolonged time to definitive deterioration in global health status/quality of life (GHS/QOL) vs placebo plus enzalutamide in...
Preclinical Study Finds FGFR2 Inhibition May Prevent Some KRAS-Expressing Pancreatic Cancers
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is also among the most deadly, with an average 5-year survival rate of less than 10%. The malignancy is often preceded by precancerous lesions. Traditional treatments of the cancer, including chemotherapy, surgery, and...
Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer
In an analysis from the phase III MIRASOL trial reported in The Lancet Oncology, Van Gorp et al found no significant difference in quality of life between patients receiving mirvetuximab soravtansine vs chemotherapy for folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer. In...
Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer
In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice. The investigators stated: “…ICIs have been...
NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma
A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...
Study Identifies Biologic Reasons for Selective Benefit of PARP Inhibitors
A newfound role for the cancer gene BRCA2 suggests why only select patients have benefited from treatment with PARP1 inhibitors to date. The results of a study by investigators at NYU Langone Health were recently published in the journal Nature. In brief, PARP inhibitors act by impairing...
Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings
Many patients who are eligible for lung cancer screening do not receive it, but do receive preventative screenings for other cancer types, according to the results of a new study published by Potter et al in JAMA. Background Although lung cancer screening is recommended for certain individuals...
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior...
Comparing Biopsy Techniques for Prostate Cancer Detection
In a U.K. trial (TRANSLATE) reported in The Lancet Oncology, Bryant et al found that local anesthetic transperineal (LATP) prostate biopsy detected more Gleason Grade Group (GGG) ≥ 2 prostate cancer compared with transrectal ultrasound (TRUS)-guided biopsy in previously biopsy-naive individuals who ...
Characteristics of Nasopharyngeal Carcinoma in the United States
In a single-center study reported in JAMA Network Open, Alsavaf et al attempted to identify patient characteristics and treatment outcomes of nasopharyngeal carcinoma in the United States, a nonendemic region of the disease. Study Details The retrospective cohort study included patients with...
Grocery Store Choice Could Impact Obesity-Related Cancer Mortality
A novel tool could help elucidate consumer behaviors at the county level as well as the relationship between the location where individuals shopped for their food and their risk of obesity-related cancer mortality, according to a recent study published by Lin et al in BMC Medicine. Background Over...
Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in...
Is Surgery Necessary to Treat Invasive Breast Cancer?
Surgery may not be necessary for patients with early-stage breast cancer who had a complete response to neoadjuvant chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center. Five-year results from the phase II...
Awareness of Alcohol-Related Cancer Risks May Be Growing
An increasing proportion of the U.S. public may be aware of the link between consuming alcohol and the elevated risk of later developing cancer, according to a recent survey conducted by the University of Pennsylvania’s Annenberg Public Policy Center (APPC). Background On January 3, 2025, Vivek...
Local Excision May Be Feasible in Patients With Low Rectal Adenocarcinoma
Chemotherapy followed by local excision may be effective in patients with node-negative low rectal adenocarcinoma, according to new findings presented by Buettner et al at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. Background The current standard of care among most patients with...
Smoking Status of the U.S. Cancer Population
In a study reported as a research letter in JAMA Oncology, Caturegli et al attempted to identify smoking status of patients diagnosed with cancer in the United States in 2023. Study Details In the cross-sectional study, the smoking status of patients diagnosed with cancer in 2023 was collected by...
Exploring Impact of the COVID-19 Pandemic on Colorectal Cancer Screening, Diagnosis
Two recent studies have elucidated the effects of the COVID-19 pandemic on colorectal cancer screenings and diagnostic colonoscopies in Central Indiana. The findings—reported by Kumar et al in PLOS One and Richter et al in Preventive Medicine Reports—contribute to the compendium of knowledge on...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines
In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines vs the prior guidelines. In 2021, the USPSTF updated lung cancer screening guidelines by...
AI Integration in Global Programs of CT Screening for Lung Cancer and Other Tobacco-Related Illnesses
A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE), has proposed a public health program of longitudinal chest computed tomography (CT) screenings among a global high-risk population of tobacco-exposed individuals utilizing...
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper-tract urothelial carcinoma. Study Details In this multicenter open-label trial, 45...
Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
Treatment Discontinuation in Patients With CML: Role of Digital PCR
The clinical application of BCR::ABL1 digital polymerase chain reaction (PCR) testing may reliably quantify stable deep molecular remission in patients with chronic myeloid leukemia (CML), which could help determine when maintenance therapy may be discontinued successfully, according to a recent...
Breast Shrinkage Following Breast-Conserving Therapy
Breast-conserving therapy, including radiation therapy, could lead to a progressive reduction in breast size over time among women with early-stage breast cancer, according to a recent study published by Becker et al in Plastic and Reconstructive Surgery. Background Breast-conserving...
Accelerated Onset of Aging-Related Diseases in Childhood Cancer Survivors?
In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases. Study Details The study focused on data from the Childhood Cancer Survivor Study and national databases...
Low-Dose CT Screening for Lung Cancer in a High-Risk Population
In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...
Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer
Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 trial. Researchers have halted this large, randomized phase II/III trial after patients in the...
Daily Physical Activity—Even at Light Intensities—May Reduce Cancer Risk
Investigators found that individuals who engaged in light- and moderate-to-vigorous–intensity physical activity daily had a lower risk of developing cancer compared with those who were more sedentary, according to a recent study published by Shreves et al in the British Journal of Sports Medicine....
